RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:That 31st site wasn't the winner!The patients would have to know what the specifications of the trial were.
They would have to be notified that they are getting X, Y, or Z.
If the parameter changed at some point from Either X or Y or Z to either X or Y the patient would know.
If the patient knows, we know.
Thus why haven't we been notified that dosage has been determined?
2 options:
1. the trial hasn't decided on a dosage as the data is too close to call AKA failure
2. they haven't recruited enough patients, likely as they continue to add sites.
Trippedstocks wrote:
dosage would have been advised by the DSMB by the Feb 26 PR. But as MF has stated, it's all confidential during the study. I don't see how they could apply for EUA without having results publicized. Who knows. I still would like to see the other IP progress as per their own set milestones in the public investors deck.